Slide 1: Investor Presentation Q1'26
Investor Presentation Q1’26 TM
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology The world’s top 20 biopharma companies trust us 26 Years > 23% 600+ Healthcare Employees With Dedicated Team For Innovative Domain Expertise Healthcare Background Technologies • Practitioner knowledge Healthcare Technology • Digital-first a
Slide 4: We Provide Capabilities and Expertise Across the Commercialization Value Chain
We Provide Capabilities and Expertise Across the Commercialization Value Chain Strategy Sales and Marketing Medical & Regulatory Affairs, R&D / Clinical Build and connect brand strategy to Pharmacovigilance Transform clinical trials by unlocking omnichannel HCP and patient engagement Communicate sci
Slide 5: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 6: Management Commentary on Q1 FY26 results
Management Commentary on Q1 FY26 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer “We continued our growth momentum in Q1FY26, delivering 1.8% “In Q1FY26, we maintained our trajectory of stable and profitable growth. growth QoQ in USD. This reflects a st
Slide 7: Q1 FY26: Financial Highlights
Q1 FY26: Financial Highlights Significant INR 7,608 Mn 0.7% 1.8% growth at scale Revenue from Operations QoQ revenue growth QoQ revenue growth in INR terms in USD terms 20.2% 15.3% Strong EBITDA Margin PAT Margin margin profile Flat QoQ 0.3% QoQ © 2025 Indegene. All rights reserved. 7
Slide 8: Q1 FY26: Business Highlights
Q1 FY26: Business Highlights Strong client 70 40 62.7% relationships Active Client Relationships Clients with $1 Million+ Revenue from Top 20 Global Revenue Biopharma* Companies Global 5,087/4,394 24.8% 16.8% Delivery Total Employees / Delivery Employees Delivery Headcount with Voluntary Attrition H
Slide 9: Q1 FY26: Business Mix
Q1 FY26: Business Mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) Revenue by Customer Geography (%) 81.1 87.4 88.9 1.1% 2.5% 2.3% 4.5% 3.0% 3.5% 12.2% 12.8% 10.0% 27.1% 2.4% 70.2% 55.4% 56.3% 58.5% 0.3% 28.0% 94.1% 27.9% 27.9% Q1FY26 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Enterprise Me
Slide 10: Q1 FY26: Segment Performance Update
Q1 FY26: Segment Performance Update Amount in INR Mn Segment performance QoQ Segment performance YoY 4,453 4,453 4,255 3,749 1,889 2,132 2,107 2,132 304 265 823 758 967 758 227 265 ECS EMS BRAND OTHERS ECS EMS BRAND OTHERS ACTIVATION ACTIVATION Q1 FY25 Q1 FY26 Q4 FY25 Q1 FY26 • Core segments (ECS &
Slide 11: Growth Approach 1: Deeper Engagement with Large Pharma Customers
Growth Approach 1: Deeper Engagement with Large Pharma Customers Amount in INR Mn Revenue from Top 5 customers Revenue from Top 20 customers 55% 49% 46% 40% 86% 84% 84% 78% 11,345 11,984 11,347 11,468 21,657 22,082 22,670 9,176 19,321 14,320 FY22 FY23 FY24 FY25 Q1 FY26 FY22 FY23 FY24 FY25 Q1 FY26 LT
Slide 12: Growth Approach 2: Broader targeting leading to a wider, taller pyramid
Growth Approach 2: Broader targeting leading to a wider, taller pyramid 70 40 24 Active clients(1) $1Mn+ Clients(1) Active clients(1) added since FY22 Active client base(1) Successful track record of growing accounts 41 40 34 35 2 2 28 3 8 7 4 4 6 3 73 2 70 62 63 46 31 31 23 26 26 FY22 FY23 FY24 FY2
Slide 13: Strategic Initiatives – FY26
Strategic Initiatives – FY26 Tectonic Sales and GTM Investments in Building M&A • Indegene’s strategic Reorg Business Capability organizational • Identified priority areas initiative on large for M&A including Data & transformative change • Strategic review of Enhancement processes Analytics capabil
Slide 14: Enhancing credibility with industry recognition
Enhancing credibility with industry recognition Analyst Recognition Awards Everest Group ISG Group Leadership Leadership position in position in AI and LS Commercial Ops 2025 MM+M Analytics Services Finalist Data Platform 2025 for Commercial 2025 IDC Avasant Major Player in Innovator in Veeva Digita
Slide 15: Financial Highlights
Financial Highlights © 2025 Indegene. All rights reserved. 15
Slide 16: Q1 FY26 Consolidated Financials
Q1 FY26 Consolidated Financials Amount in INR Mn Particulars Q1 FY26 Q4 FY25 Q1 FY25 QoQ % YoY% Revenue from Operations 7,608 7,556 6,765 0.7% 12.5% Employee Benefit Expenses 4,815 4,851 4,443 -0.7% 8.4% Other Expenses 1,240 1,230 1,033 0.8% 20.0% Other Income -17 51 39 -132.8% -142.9% EBITDA 1,536
Slide 17: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet EBITDA and EBITDA Margin PAT and PAT Margin Cash and Cash Equivalent(1) INR Mn and % INR Mn and % INR Mn 15.6% 15.3% 20.2% 20.2% 19.6% 13.0% 1,526 1,536 1,176 1,164 17,280 16,643 1,328 13,973 877 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25
Slide 18: Thank You!
Thank You! www.indegene.com
Slide 19: Fact Sheet
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2026 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Jun 30, Mar 31, Jun 30, No. YoY QoQ 2025 2025 2024 1. Active clients (1) (No.) 70 73 65 2. Revenue from operations 7,608 7,5
Slide 20: Fact Sheet
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2026 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Jun 30, Mar 31, Jun 30, YoY QoQ 2025 2025 2024 Biopharma 94.1 94.0 93.5 13.2 0.8 Medical Devices 2.5 2.6 2.7 2.6 -4.0 Emerging Biotech 2.3 2.3 2.6 0